Back Hepatitis B

Hepatitis B

AASLD Liver Meeting Starts this Weekend in Boston

The American Association for the Study of Liver Diseases (AASLD) annual Liver Meeting gets underway this weekend, running through November 11 at the Hynes Convention Center in Boston. Once again, this year's meeting will highlight interferon-free direct-acting antiviral regimens for hepatitis C.

alt

Read more:

IDWeek 2014: Hepatitis B Relapse Is Common After Stopping Antiviral Therapy

Hepatitis B virus (HBV) rebounded in nearly 80% of people treated with fully or partially suppressive antiviral therapy using adefovir (Hepsera), entecavir (Baraclude), lamivudine (Epivir), or tenofovir (Viread), indicating that long-term therapy is usually needed to control the virus, researchers reported at IDWeek 2014 last month in Philadelphia.

alt

Read more:

Everolimus Did Not Improve Survival for Advanced Liver Cancer Patients

The mTOR inhibitor everolimus (Afinator) failed to increase overall survival for people with advanced hepatocellular carccinoma (HCC) who were previously unsuccessfully treated with sorafenib, according to results from the EVOLVE-1 trial published in the July 2 edition of JAMA.

alt

Read more:

HIV Controllers Respond Better to Hepatitis B Vaccine

HIV positive natural controllers who maintain undetectable or low viral load without antiretroviral therapy (ART) are more likely to achieve adequate response to hepatitis B virus (HBV) vaccination and have improved survival, according to a study published in the August 21 edition of the open-access journal PLoS ONE.

alt

Read more:

No Tenofovir Resistance Seen In 2 Years of Hepatitis B Treatment

No cases of resistance to tenofovir (Viread) were detected among chronic hepatitis B patients with prior resistance to lamivudine (3TC or Epivir) through 96 weeks of treatment, according to a study described in the June 11 advance edition of Clinical Gastroenterology and Hepatology. Adding emtricitabine (Emtriva) did not improve effectiveness compared with tenofovir alone.

alt

Read more:

Novel Lab Technique May Aid Study of New Hepatitis B Treatments

A laboratory model of the hepatitis B virus (HBV) lifecycle using a stem cell technique that maintains the virus in liver cells may help researchers d

alt

evelop new treatments for the disease, according to a report in the August 4 advance edition of the Proceedings of the National Academy of Sciences.

Read more:

Antiviral Treatment for Hepatitis B Lowers Risk of Liver Cancer

Antiviral therapy for chronic hepatitis B virus (HBV) infection can reduce the risk of developing hepatocellular carcinoma (HCC), even among people with high HBV viral load, according to research described in the May 2014 edition of Clinical Gastroenterology and Hepatology.

alt

Read more:

HBV Rebounds After Stopping Entecavir, Switching to Interferon May Help

Most hepatitis B "e" antigen (HBeAg) negative chronic hepatitis B patients relapsed after stopping treatment with the antiviral drug entecavir (Baraclude), according to a report in the May 15 online edition of Gut. A related study found that switching from entecavir to pegylated interferon increased the likelihood of HBeAg seroconversion and hepatitis B surface antigen(HBsAg) lossin HBeAg positive patients.

alt

Read more:

Screening and Post-Natal Prophylaxis Reduce Mother-to-Child HBV Transmission

Prenatal screening of pregnant women for hepatitis B virus (HBV), followed by immune prophylaxis for infants using injected hepatitis B antibodies and the first dose of the HBV vaccine given soon after delivery, resulted in a low rate of vertical HBV transmission -- less than 1 per 100 births -- in a real-world study described in the May 27 advance edition of Annals of Internal Medicine.

alt

Read more: